上海医药公告，下属正大青春宝药业有限公司研发的"七味防己黄芪颗粒"收到国家药品监督管理局核准 签发的《药物临床试验批准通知书》。该药物为颗粒剂型，用于慢性心力衰竭的临床试验。项目由青春 宝与天津中医药大学等合作研发，累计投入研发费用约1380万元人民币。该产品尚未在国内外上市。 ...

上海医药公告，下属正大青春宝药业有限公司自主研发的"芪苓颗粒"收到国家药品监督管理局核准签发 的《药物临床试验批准通知书》。芪苓颗粒为颗粒剂，用于痛风发作间歇期湿浊瘀阻证的临床试验。芪 苓颗粒处方源自杭州市中医院的临床验方，由青春宝自主研发，拥有核心知识产权。截至本公告披露 日，该项目已累计投入研发费用约1142万元人民币。 ...

证券之星消息，1月28日医药商业板块较上一交易日下跌1.0%，人民同泰领跌。当日上证指数报收于 4151.24，上涨0.27%。深证成指报收于14342.9，上涨0.09%。医药商业板块个股涨跌见下表： 从资金流向上来看，当日医药商业板块主力资金净流出5.28亿元，游资资金净流出7430.02万元，散户资 金净流入6.03亿元。医药商业板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600056 | 中国医药 | 3214.63万 | 5.42% | -1657.53万 | -2.80% | -1557.11万 | -2.63% | | 000950 | 重药控股 | 2310.52万 | 9.36% | -515.37万 | -2.09% | -1795.15万 | -7.27% | | 603883 | 老百姓 | 1263.92万 | 3.83% | 1194.90万 | 3.62% ...

内容概要：随着我国人口老龄化进程日益加剧，心脑血管疾病高发人群数量也不断增加，高血压、高血 脂等基础慢性疾病患病率持续攀升，带动心脑血管药物市场需求不断增加，与此同时，随着居民健康意 识不断增强，对心脑血管疾病早筛早治的重视程度显著提升，用药干预周期显著前移，进一步拓宽了心 脑血管药物的适用人群边界，此外，医保政策对心脑血管药物的覆盖范围与保障力度持续加大，有效提 升患者用药可及性，持续释放临床刚性用药需求，但另一方面，随着药品集中带量采购常态化推进，心 脑血管药物价格进入下行通道，行业整体市场规模随之承压收缩，据统计，2025 年我国心脑血管中成 药市场规模已回落至 954.1 亿元，心脑血管化学药市场规模则降至 1415.8 亿元。 相关上市企业：华润医药（03320.HK）、康方生物（09926.HK）、信达生物（01801.HK）、石药集团 （01093.HK）、信立泰（002294）、以岭药业（002603）、恒瑞医药（600276）、步长制药 （603858）、上海医药（601607）、同仁堂（600085） 方管理的通知》《关于完善医药集中带量采购和执行工作机制的通知》《关于加快推进中医优势专科 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval and Indications - Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The product's research and development were completed by Changzhou Pharmaceutical Factory in October 2019, and it received approval from the U.S. Food and Drug Administration in July 2021 [1] Group 2: Market Expansion and Investment - The drug has also been approved for market entry in Thailand by June 2025, indicating a strategic expansion into Southeast Asian markets [1] - The company has invested approximately RMB 2.19 million in research and development for the product's launch in Southeast Asia, which includes Thailand, Singapore, Malaysia, and the Philippines [1]

Group 1 - Shanghai Pharmaceuticals has received approval for the production of Avatrombopag Maleate Tablets from the National Medical Products Administration [1][2] - The drug is indicated for adult patients with chronic liver disease-related thrombocytopenia undergoing elective diagnostic procedures or surgery, and for adults with chronic primary immune thrombocytopenia (ITP) who have had inadequate responses to previous treatments [3] - The company has invested approximately RMB 9.8961 million in the research and development of this drug as of the announcement date [3] Group 2 - The drug's approval is expected to enhance market share and competitiveness, benefiting from greater support in medical insurance and procurement due to its new registration classification [5] - The total procurement amount for Avatrombopag Maleate Tablets in hospitals in mainland China is projected to be RMB 566.56 million in 2024 [4] Group 3 - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate for Pregabalin Capsules from the Health Sciences Authority of Singapore, allowing it to market the drug in Singapore [8][9] - Pregabalin Capsules are indicated for the treatment of neuropathic pain and as an adjunct therapy for epilepsy, with a total investment of approximately RMB 2.19 million in R&D for the Southeast Asian market [9] - The sales revenue for Pregabalin Capsules in Singapore is estimated to be USD 2 million in 2024 [11]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for the drug Pregabalin capsules, which has been approved for market launch [1]. Group 1 - The drug Pregabalin capsules have been officially approved for sale in Singapore [1]. - The approval was granted by the Health Sciences Authority (HSA) of Singapore [1].

北京商报讯（记者 王寅浩 宋雨盈）1月23日，上海医药发布公告称，公司下属常州制药厂有限公司生产 的普瑞巴林胶囊收到新加坡食品药品监督管理局发的药品注册证书，该药品获得批准上市。根据公告， 普瑞巴林胶囊主要用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌痛和脊髓损伤引起的神经性 疼痛以及癫痫的辅助治疗。 ...

Core Viewpoint - The recent policy document issued by multiple government departments aims to promote high-quality development in the pharmaceutical retail industry, leading to a surge in stock prices of major pharmacy chains in the A-share market [1][3]. Group 1: Policy Measures - The policy document outlines 18 specific measures to enhance the pharmaceutical retail sector, focusing on professionalization, digitalization, and regulatory compliance [1]. - Key initiatives include improving pharmacy service capabilities, supporting mergers and acquisitions among retail pharmacies, and fostering a fair competitive market environment [2]. Group 2: Market Impact - The policy is expected to drive mergers and acquisitions, increasing industry concentration and facilitating the transition of pharmacies from "drug sales" to "comprehensive services" [2]. - Leading pharmacy chains such as Yifeng Pharmacy and Dacelins have seen significant stock price increases, with Yifeng's store count projected to exceed 14,666 by September 2025, and Dacelins operating 17,385 stores [3]. Group 3: Benefits to Other Companies - Other pharmaceutical companies like Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong are anticipated to benefit from the integration of wholesale and retail operations, enhancing their revenue potential [3]. - The policy encourages retail pharmacies to enhance their service capabilities, which may benefit digital and supply chain service providers in the healthcare sector [4].

格隆汇1月23日丨上海医药(02607.HK)发布公告，近日，公司下属常州制药厂有限公司(以下简称"常州 制药厂")生产的普瑞巴林胶囊收到新加坡食品药品监督管理局(HSA)颁发的药品注册证书，该药品获得 批准上市。普瑞巴林胶囊主要用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌痛和脊髓损伤引 起的神经性疼痛以及癫痫的辅助治疗。 ...